SIGLEC7-KO iPSC-derived NK cells

SIGLEC7-KO iPSC-derived NK cells are genetically engineered natural killer (NK) cells differentiated from human induced pluripotent stem cells (iPSCs) in which the gene encoding Sialic acid-binding immunoglobulin-like lectin 7 (Siglec-7, SIGLEC7) has been knocked out to enhance anti-tumor activity. Siglec-7 is an inhibitory receptor expressed on mature NK cells that dampens NK cell degranulation and interferon-γ production upon engagement, so its deletion is intended to relieve inhibitory signaling and augment NK cell cytotoxicity, cytokine secretion, and resistance to tumor-mediated immune suppression.[2][3] As an allogeneic, off-the-shelf iPSC-derived NK cell product, this modality leverages clonal iPSC engineering and large-scale expansion to generate a standardized NK cell therapy platform, primarily being explored preclinically for cancer immunotherapy, particularly against solid tumors and hematologic malignancies.[1][3]